Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection
Status:
Completed
Trial end date:
2021-03-13
Target enrollment:
Participant gender:
Summary
This study was designed as a randomized, double-blind, parallelity-controlled
study.Eighty-eight healthy male subjects (44 in each group) will be enrolled in this
study.The aim of this clinical trial is to evaluate pharmacokinetic similarity between
recombinant monoclonal antibody against human epidermal growth factor receptor injection
(HS627) and Perjeta ® in a single intravenous infusion in healthy male subjects.